Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2018-05-18 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2018-05-18 English
Special Business Approved at AGM
AGM Information Classification · 19% confidence
2018-05-18 English
AstraZeneca update on Fasenra PIII trial in COPD
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated May 11, 2018. It announces top-line results from a Phase III clinical trial (GALATHEA) for a drug (Fasenra) in COPD. This is a specific corporate announcement regarding clinical trial outcomes, which is typically disseminated via regulatory news services. Since it is a specific announcement of clinical trial results and not a comprehensive financial report (like 10-K or IR), nor a general management change (MANG), the most appropriate category is the general regulatory announcement fallback, RNS, as it is explicitly labeled as an RNS release and contains time-sensitive, non-financial operational news.
2018-05-11 English
6-K Filing
Regulatory Filings
2018-05-11 English
EMA approves Lynparza: maintenance ovarian cancer
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content announces the EU approval of the drug LYNPARZA for ovarian cancer treatment, detailing efficacy data from clinical trials (SOLO-2 and Study 19), executive quotes, and background information on the drug and the companies involved (AstraZeneca and MSD). This is a substantive announcement of a major corporate/product development, not just a notice that a report is attached. Since it is a general regulatory announcement that doesn't fit the specific categories like ER (Earnings Release), AR (Audit Report), or DIV (Dividend Notice), the most appropriate classification is the general regulatory filing category, RNS.
2018-05-08 English
AZ and Luye Pharma enter agreement for Seroquel
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details a significant business transaction: the sale and license of rights for Seroquel and Seroquel XR to Luye Pharma Group, including financial considerations ($538m). This type of announcement, concerning asset divestiture, partnership, or major corporate transaction that is not a standard periodic report (like 10-K or IR), typically falls under general regulatory filings or M&A activity. Since it is an announcement of a specific transaction rather than a merger proposal (TAR), and it is clearly distributed via RNS, the most appropriate general classification is Regulatory Filings (RNS). It is not a Call Transcript (CT), Earnings Release (ER), or a formal report like 10-K or IR.
2018-05-08 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.